Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NGL Fine-ChemNSE:NGLFINE -1.79%78 ROC (Joel Greenblatt) % is 19.26% as of Mar. 2026, which is 26% below its 10-year median of 26.06. GuruFocus rates NSE:NGLFINE with a GF Score™ of 78/100 and a GF Value™ of ₹2,845.05 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 981 Drug Manufacturers companies, NGL Fine-Chem ranks better than 64.02% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. NGL Fine-Chem's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 19.26%.
The historical rank and industry rank for NGL Fine-Chem's ROC (Joel Greenblatt) % or its related term are showing as below:
NSE:NGLFINE'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 11.3 Med: 26.06 Max: 64.08
Current: 20.19
During the past 13 years, NGL Fine-Chem's highest ROC (Joel Greenblatt) % was 64.08%. The lowest was 11.30%. And the median was 26.06%.
NSE:NGLFINE's ROC (Joel Greenblatt) % is ranked better than 64.02% of 981
companies
in the Drug Manufacturers industry
Industry Median: 11.46
vs NSE:NGLFINE: 20.19
NGL Fine-Chem's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -23.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
NGL Fine-Chem ROC (Joel Greenblatt) % Related Terms
NGL Fine-Chem ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for NGL Fine-Chem's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NGLFINE vs LLY, JNJ, ABBV: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - General subindustry, NGL Fine-Chem's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NGL Fine-Chem ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where NGL Fine-Chem's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 19.26% mean?
NGL Fine-Chem (NSE:NGLFINE) has a ROC (Joel Greenblatt) % of 19.26% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on NGL Fine-Chem and its competitors. This is 26% below median its historical median of 26.06. Over the past decade, NGL Fine-Chem's ROC (Joel Greenblatt) % has ranged from 11.30 to 64.08. According to the industry distribution chart, NGL Fine-Chem ranks #353 out of 981 companies in the Drug Manufacturers industry, placing it in the top 36%.
Is NGL Fine-Chem's ROC (Joel Greenblatt) % too high?
NGL Fine-Chem's current ROC (Joel Greenblatt) % of 19.26% is 26% below median its 10-year median of 26.06. Over the past 10 years, this metric has ranged from a low of 11.30 to a high of 64.08. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.46. NGL Fine-Chem's value of 19.26% is 68.1% above this industry median. Based on the distribution chart, NGL Fine-Chem ranks #353 out of 981 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, NGL Fine-Chem has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NGL Fine-Chem's ROC (Joel Greenblatt) % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, NGL Fine-Chem ranks #353 out of 981 companies for ROC (Joel Greenblatt) %. This puts NGL Fine-Chem in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.46. NGL Fine-Chem's value of 19.26% is 68.1% above this benchmark. Historically, NGL Fine-Chem's own ROC (Joel Greenblatt) % has ranged from 11.30 to 64.08 over the past decade. While the company's 10-year median is 26.06 vs. the industry median of 11.46, NGL Fine-Chem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NGL Fine-Chem's current ROC (Joel Greenblatt) % of 19.26% is 68.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on NGL Fine-Chem and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NGL Fine-Chem's current ROC (Joel Greenblatt) % is 19.26%, which is 26% below median its own 10-year median of 26.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NGL Fine-Chem stock overvalued right now?
Based on GuruFocus' analysis, NGL Fine-Chem (NSE:NGLFINE) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,845.05, compared to a current price of ₹3,198.00 — trading 12.4% above its estimated fair value. The current ROC (Joel Greenblatt) % is 19.26%, which is 26% below median its 10-year median of 26.06 and 68.1% above the Drug Manufacturers industry median of 11.46. NGL Fine-Chem's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For NGL Fine-Chem (NSE:NGLFINE), the current ROC (Joel Greenblatt) % is 19.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?
Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued.
The current stock price of ₹3,198.00 is trading 12.4% above its estimated GF Value™ of ₹2,845.05.
GuruFocus considers NGL Fine-Chem to be Modestly Overvalued.
Key valuation signals for NSE:NGLFINE:
ROC (Joel Greenblatt) %: 19.26% (26% below median its 10-year median of 26.06)
GF Value™: ₹2,845.05 vs. price of ₹3,198.00 (12.4% above fair value)
Industry Position: 68.1% above the Drug Manufacturers median (#353 of 981)
No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
78GF Score
Get the complete analysis for NSE:NGLFINE
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NGLFINE has been successfully added to your 
